

# WHO TB Vaccine Accelerator Council Finance and Access Working Group

## *Civil Society Information Session*

28<sup>th</sup> May 2025



World Health  
Organization

# Agenda *(in CEST)*

**Chair of meeting:** Mike Frick, Co-Director, Tuberculosis project, Treatment Action Group

## **Introduction**

- **Welcome and Opening Remarks** (14.00 – 14.05) (Mike Frick, Chair)
- **Update on TB Programme** (14.05 – 14.10) (Matteo Zignol, Unit Head – Prevention, Diagnosis, Treatment, Care & Innovation, Global Programme on Tuberculosis and Lung Health, WHO)

## **Update from Co-Convenors on WHO TB Vaccine Accelerator Finance & Access Working Group**

- **Presentation on F&A WG** (14.10 – 14.25) (Tara Prasad, Team Lead –Global Vaccine Access, Immunization, Vaccines and Biologicals department, WHO)
- **Remarks from Gavi** (14.25 – 14.30) (Dominic Hein, Director – Market Shaping, Gavi)
- **Remarks from Govt. of South Africa** (14.30 – 14.35) (Norbert Ndjeka, Chief Director – TB Control and Management, National Department of Health)

## **Questions and Answers**

**Q&A** (14:35-14:55) (All, moderated by Mike Frick, Chair)

## **Closing**

**Wrap up and next steps** (14.55 – 15.00) (Mike Frick, Chair)

# Welcome and Opening Remarks (Mike Frick, Chair)



World Health  
Organization

# Update on TB Programme (Matteo Zignol, WHO)



World Health  
Organization

# Presentation on Finance & Access Working Group (Tara Prasad, WHO)



World Health  
Organization

# New, improved tuberculosis vaccines for adolescents & adults are anticipated to have the highest impact

## The TB Burden

- More than **10 M** people falling ill every year ( > 90% adolescents and adults)
- **3500 deaths/day**
- Only licensed vaccine (BCG) is not effective in preventing disease among adolescents and adults



WHO Preferred Product Characteristics for New Tuberculosis Vaccines

An investment case for new tuberculosis vaccines

World Health Organization










Vaccines	Vaccine for <b>adolescents &amp; adults</b> (50% efficacy in preventing disease)	Improved vaccine for <b>infants</b> (80% efficacy in preventing disease)
TB <b>cases</b> averted	<b>37.2 – 76.0 million</b> cases	<b>5.8–18.8 million</b> cases
TB <b>deaths</b> averted	<b>4.6– 8.5 million</b>	<b>0.8–2.6 million</b>
Fighting <b>antimicrobial resistance</b>	Avert <b>21.9–42.3 million</b> treatments & save <b>US\$ 3.2 billion</b> in treatment costs	Avert <b>2.4–8.6 million</b> treatments & save <b>US\$ 299 million</b> in treatment costs
Gains in <b>GDP</b>	US\$ 1.6 (0.8–3.0) trillion	US\$ 0.2 (0.1–0.4) trillion

# In 2023, WHO launched the TB Vaccine Accelerator Council














Aims to support the community of key stakeholders accelerate the development, approval and use effective novel TB vaccines, as part of the basket of interventions to combat TB

### Members of the Ministerial Board

<b>Dr Nísia Trindade Lima (Co-chair)</b> <i>Minister of Health, Brazil</i>	
<b>Dr Budi Gunadi Sadikin (Co-chair)</b> <i>Minister of Health, Indonesia</i>	
<b>Mr Aurélien Rousseau</b> <i>Minister of Social Affairs and Health, France</i>	
<b>Dr Deborah Mlongo Barasa</b> <i>Cabinet Secretary for Health, Kenya</i>	
<b>Ms Dao Hong Lan</b> <i>Minister of Health, Viet Nam</i>	
<b>Dr Malik Mukhtar Ahmed Bharath</b> <i>Coordinator to Prime Minister on Health, Pakistan</i>	
<b>Dr Aaron Motsoaledi</b> <i>Minister of Health, South Africa</i>	
<b>Dr Teodoro J. Herbosa</b> <i>Secretary of Health, Philippines</i>	
<b>National Institutes of Health</b> <i>National Institutes of Health, United States of America</i>	


### Members of the Principal Group

<b>Dr Akinwumi Adesina</b> <i>President, African Development Bank Group</i>	
<b>Dr Trevor Mundel</b> <i>President of Global Health, Bill and Melinda Gates Foundation</i>	
<b>Ms Nadia Calvino</b> <i>President, European Investment Bank</i>	
<b>Dr Juan Pablo Uribe</b> <i>Global Director for Health, Nutrition &amp; Population and the Global Financing Facility, World Bank</i>	
<b>Dr Sania Nishtar</b> <i>Chief Executive Officer, Gavi, the Vaccine Alliance</i>	
<b>Mr Peter Sands</b> <i>Executive Director, Global Fund</i>	
<b>Dr Philippe Duneton</b> <i>Executive Director, Unitaid</i>	
<b>Dr John-Arne Rattingen</b> <i>Chief Executive Officer, Wellcome Trust</i>	
<b>Dr Lucica Ditiu</b> <i>Executive Director, Stop TB Partnership</i>	
<b>Mike Frick</b> <i>Co-Director of Tuberculosis Project, Treatment Action Group</i>	



In 2024, commitment to convene stakeholders in 2025 to discuss options for procurement and financing of late-stage vaccines

# TB Vaccine Accelerator value chain



## The Council



- Brings together high-level representatives of governments, civil society, donors, and partners.
- Provides strategic direction and political advocacy

## Accelerator working groups



- Agile, integrated platform of technical and strategic working groups
- Improves collaboration and co-ordination from discovery to delivery

## Accelerator Secretariat



- Work within the vaccine community to first establish and then support the Accelerator working groups
- Co-leads of the working groups will collectively form a steering committee to inform the Accelerator Secretariat and Council (envisaged)



# In 2025, WHO launched the global Finance & Access Working Group

## Progress update report of the TB Vaccine Accelerator Council: November 2024-February 2025

24 April 2025 | Meeting report

### 2. Establishment of the finance and access working group

In May 2024, Members of the Council requested the WHO Secretariat to establish working groups to accelerate the achievement of goals aligned to its mission. Four working groups will be established in a phased approach: vaccine research, and innovation; product development, policy & manufacturing; finance & access; and country readiness, advocacy, & community partnership.

The finance and access working group was established in February 2025.

In February 2025, the TB Accelerator launched the [Finance and Access Working Group](#) with the goal of ensuring timely, equitable, and sustainably financed access to affordably priced new TB vaccines in all countries with demand based on public health needs. The Working Group held its **first meeting on 14 February 2025** and will continue to meet monthly thereafter. It is **co-convened** by South Africa, WHO, and Gavi, each bringing distinct expertise in vaccine financing and access. Members include representatives of governments, health and development partners, financing institutions, academia, and civil society.

[Progress update report of the TB Vaccine Accelerator Council: November 2024-February 2025](#)



#### Government of South Africa



**Norbert Ndjeka**  
Chief Director – TB Control and Management, National Department of Health



**Lindiwe Mvusi**  
Director – TB Control and Management, National Department of Health

#### GAVI, the Vaccine Alliance



**Dominic Hein**  
Director – Market Shaping, Gavi, the Vaccine Alliance



**Marion Menozzi-Arnaud**  
Senior Specialist– Market Shaping, Gavi, the Vaccine Alliance



**Tiziana Scarna**  
Senior Manager – Market shaping, Gavi, the Vaccine Alliance

#### WHO




**Tara Lavanya Prasad**  
Team Lead –Global Vaccine Access, Immunization, Vaccines and Biologicals department, WHO



**Matteo Zignol**  
Unit Head – Prevention, Diagnosis, Treatment, Care & Innovation, Global Tuberculosis Programme, WHO


Co-convened by **WHO, Gavi and the Government of South Africa**

# Importance of early access and financing considerations



*This figure is illustrative and non-exhaustive*

# Equitable access to novel TB vaccines in low- and middle-income countries is a priority



Map is showing estimated TB incidence rate in 2023 ([Global TB Report, 2024](#))

# Finance and Access Working Group – Vision and Terms of Reference

## Objective:

To promote timely, equitable and sustainably financed access to affordably priced new TB vaccines in all countries where there is demand for these vaccines, driven by public health need, fostering sustainable supply

## Goals



- Develop an early understanding of anticipated barriers, bottlenecks, challenges and supply-demand dynamics relevant to country financing and access for novel TB vaccines
- Accelerate the identification of financing and access solutions and opportunities to incentivize equitable and affordable global access
- Develop a financing and access options framework, outlining mechanisms that enable countries to have timely and sustainable access to novel TB vaccines
- Coordinate efforts across governments, partners, financing institutions, private sector, and civil society to propose strategic partnerships and financing and access mechanisms with global applicability, while maintaining a particular focus on speeding up vaccine availability and access for high TB-burden countries
- Foster the development and implementation of financing and access strategies that enable countries to have timely and sustainable access to safe, effective, and affordably priced TB vaccines.

# Finance and Access Working Group Members List

## Co-Conveners



### Norbert Ndjeka

Chief Director – TB Control and Management, National Department of Health



### Lindiwe Mvusi

Director – TB Control and Management, National Department of Health



### Dominic Hein

Director – Market Shaping, Gavi, the Vaccine Alliance



### Marion Menozzi-Arnaud

Senior Specialist – Market Shaping, Gavi, the Vaccine Alliance



### Tiziana Scarna

Senior Manager – Market shaping, Gavi, the Vaccine Alliance



### Tara Lavanya Prasad

Team Lead – Vaccine Global Access, Immunization, Vaccines and Biologicals department, WHO



### Matteo Zignol

Unit Head – Prevention, Diagnosis, Treatment, Care & Innovation, Global Programme on Tuberculosis and Lung Health, WHO



### Santiago Cornejo

Executive Director, Revolving Fund for Access to Vaccines, Pan American Health Organization (*alternate: Murat Ozturk, Supply Chain Advisor*)



### Dinesh Arora

Principal Health Specialist, Asia Development Bank



### Cristina Niculesc

Life Science Investment Specialist, EIB (*alternate: Valeria Iansante, Life Science Specialist*)



### Nicolas (Nick) Menzies

Associate Professor of Global Health, Harvard TH Chan School of Public Health



### Richard White

Professor of Infectious Disease Modelling, London School of Hygiene and Tropical Medicine



### Mike Frick

Co-Director, Tuberculosis project, Treatment Action Group



### Andrew Jones

Deputy Director, UNICEF Supply Division Vaccine Centre



### Eliud Wandwalo

Head, TB, Global Fund to Fight AIDS, TB and Malaria (*alternate: Grania Brigden, Senior TB Advisor*)



### Guy Pickles

Head of Vaccines, MedAccess (*alternate: Gillian Leitch, Head, HIV, TB and Antimicrobial Resistance*)

## Permanent members



### Frauke Uekermann

Director, Vaccine Markets, Clinton Health Access Initiative (*alternate: Verena Damovsky, Clinton Health Access Initiative*)



### Abebe Genetu Bayih

Ag. Lead Local Manufacturing of Health Commodities, Africa Centres for Disease Control and Prevention



### Erlina Burhan

Pulmonologist, Head of TB Expert, Coalition Against TB Faculty of Medicine, Universitas Indonesia – Persahabatan Hospital



### Dauda Foday Suma

Principal Industrial/Manufacturing Development Officer, Africa Development Bank



### Ana Liza Hombrado Duran

Director, Research Institute for Tropical Medicine



### Éder Gatti



Director, National Immunization Program




### Bonanza Perwira Taihitu

Senior Advisor to Minister of Health, Politics and Global Health

# Other knowledge partners



# High-level 2025 workplan





# Key technical analyses of Finance and Access Working Group

## Analysis of licencing agreements and access provisions



Licensing and access strategies for late-stage TB vaccine candidates are crucial for equitable distribution, geographically diverse manufacturing and long-term supply sustainability.

## Map 5 country specific access & financing plans



Gain insights into country-specific demand for introducing new TB vaccines and scaling up demand over time, financial commitments to new TB vaccines, and potential barriers or conditions for access.

## Map financing sources, needs & gaps



To ensure sustainable immunization programmes, it is essential to identify any financing gaps for vaccine procurement, to develop early solutions to fill these gaps and accelerate access

## Develop supply & demand forecasts



Will market shaping interventions be needed to ensure an impactful global launch and roll-out of novel tuberculosis vaccines for adolescents and adults



# Towards a high-level summit on financing & access for new TB vaccines

## Proposed Venue and Date

- Scheduled as an event during the 2025 G20 (4Q 2025)

## Key Summit Outcomes

- Launch a **shared goal for novel TB vaccine equitable access**
- Launch the **TB vaccine finance and access framework for action**, outlining mechanisms that help countries gain timely, reliable access to safe, effective, and affordably priced new TB vaccines

## Follow up Actions

- Voluntary declaration of **specific commitments for action** (such as funding and procurement pledges by governments, IP holders, suppliers, philanthropy, regional banks and global partners)

# Remarks from Gavi (Dominic Hein, Gavi)



World Health  
Organization

# Remarks from Government of South Africa

(Norbert Ndjeka, National Department of Health)



World Health  
Organization

# Questions and Answers



**World Health  
Organization**

# Closing and Next Steps (Mike Frick, Chair)



World Health  
Organization